Emergent BioSolutions Inc.
$8.35
▼
-1.79%
2026-04-21 06:33:00
www.emergentbiosolutions.com
NYQ: EBS
Explore Emergent BioSolutions Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$445.43 M
Current Price
$8.35
52W High / Low
$14.06 / $4.45
Stock P/E
8.47
Book Value
$10.03
Dividend Yield
—
ROCE
9.47%
ROE
10.46%
Face Value
—
EPS
$0.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
900
Beta
2.36
Debt / Equity
111.69
Current Ratio
5.01
Quick Ratio
2.41
Forward P/E
2.66
Price / Sales
0.55
Enterprise Value
$790.4 M
EV / EBITDA
3.78
EV / Revenue
1.06
Rating
Strong Buy
Target Price
$12
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Rockwell Medical, Inc. | $0.94 | — | $37.03 M | — | -9.86% | -15.28% | $2.1 / $0.78 | $0.94 |
| 2. | Akanda Corp. | $3.42 | — | $1.89 M | — | -102.48% | -60.86% | $209.03 / $2.29 | $22.67 |
| 3. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 4. | Incannex Healthcare Inc. | $3.84 | — | $51 M | — | — | -1.3% | $49.8 / $2.4 | $6.13 |
| 5. | Dr. Reddy's Laboratories Limited | $12.97 | 17.86 | $11.1 B | 0.65% | 19.86% | 16.1% | $1,379.7 / $1,129 | $4.78 |
| 6. | Assertio Holdings, Inc. | $18.14 | — | $116.08 M | — | -12.35% | -28.25% | $20.45 / $8.55 | $14.63 |
| 7. | Universe Pharmaceuticals INC | $3.32 | — | $1.9 M | — | -5.19% | -7.23% | $11 / $2 | $99.64 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 143.8 M | 222 M | 130.3 M | 209.1 M | 189.3 M | — |
| Operating Profit | -15.7 M | 76.5 M | 1.6 M | 49.9 M | -9.5 M | — |
| Net Profit | -54.6 M | 51.2 M | -12 M | 68 M | -31.3 M | — |
| EPS in Rs | -1.06 | 0.99 | -0.23 | 1.32 | -0.61 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 705.2 M | 1.01 B | 1.02 B | 1.08 B |
| Operating Profit | 112.3 M | -81.5 M | -201.5 M | -163.3 M |
| Net Profit | 52.6 M | -190.6 M | -760.5 M | -211.6 M |
| EPS in Rs | 1.02 | -3.69 | -14.73 | -4.1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.32 B | 1.39 B | 1.82 B | 3.17 B |
| Total Liabilities | 796 M | 906.9 M | 1.17 B | 1.78 B |
| Equity | 522.6 M | 482.8 M | 649.3 M | 1.39 B |
| Current Assets | 662.5 M | 598.7 M | 679.5 M | 1.21 B |
| Current Liabilities | 132.2 M | 162.4 M | 651.3 M | 1.23 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 170.6 M | 58.7 M | -206.3 M | -34.1 M |
| Investing CF | 69.4 M | 125.2 M | 212.3 M | -381.3 M |
| Financing CF | -136.6 M | -190 M | -535.7 M | 481.2 M |
| Free CF | 156.8 M | 35.8 M | -257.9 M | -149.9 M |
| Capex | -13.8 M | -22.9 M | -51.6 M | -115.8 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -30.43% | -0.92% | -4.93% | — |
| Earnings Growth % | 127.6% | 74.94% | -259.4% | — |
| Profit Margin % | 7.46% | -18.8% | -74.34% | -19.66% |
| Operating Margin % | 15.92% | -8.04% | -19.7% | -15.18% |
| Gross Margin % | 53.74% | 32.78% | 31.05% | 35.59% |
| EBITDA Margin % | 33.74% | 3.64% | -50.65% | -3.57% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.